Accuracy Characterization Study

Type2 Diabetes Clinical Trial

— ACS  

Official title:

Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System Compared to Venous and Capillary Glucose

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01932944
• Other study ID #: ADC13-126
• Status: Completed
• Phase: N/A
• First received: August 28, 2013
• Last updated: January 23, 2017
• Start date: August 2013
• Est. completion date: March 2014

Study information

• Verified date: January 2017
• Source: Abbott Diabetes Care
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To demonstrate point accuracy of the Abbott Sensor Based Glucose Monitoring System (System) interstitial glucose results against venous glucose reference and capillary fingerstick using the Consensus Error Grid over the wear duration. During the course of the wear duration, the subject is required to be testing fingerstick glucose measurement at least 8 times a day for capillary reference glucose measurements and three in-clinic visits of maximum 10 hours each for venous reference glucose measurements. With every reference measurement, the subject or study staff will perform a measurement on the System.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: March 2014
• Est. primary completion date: October 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject must be at least 18 years of age.

2. Subject must have type 1 or type 2 diabetes for at least 2 years prior to enrollment.

3. Subject must require insulin therapy through an insulin pump and/or multiple daily insulin injections (at least 3 injections daily) for at least 6 months prior to enrollment.

4. Subject must be able to read and understand English.

5. In the Investigator's opinion, the Subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.

6. Subject must be available to participate in all study visits up to a period of 14 days.

7. Subject must be willing and able to provide written signed and dated informed consent.

Exclusion Criteria:

1. Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.

2. Subject is pregnant, attempting to conceive or not willing and able to practice birth control during the study duration.

3. Subject has skin lesions, scarring, redness, infection or edema at the application sites that could interfere with device placement or the accuracy of interstitial glucose measurements.

4. Subject currently is participating in another clinical trial.

5. Subject has donated blood within 112 days prior to the beginning of the study activities.

6. Subject has concomitant medical condition which, in the opinion of the Investigator, could interfere with the study or present a risk to the safety or welfare of the Subject or study staff. Such conditions include but are not limited to:

• History of HIV, Hepatitis B or C, or other blood-borne pathogen;

• Subject has an increased risk of bleeding.

• Subject has X-ray, MRI or CT appointment scheduled during the period of study participation, and the appointment cannot be rescheduled for a time before study participation starts or after study participation ends.

• Subject is unsuitable for participation due to any other cause as determined by the Investigator.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Insulin Dependent Diabetes
• Type1diabetes
• Type2 Diabetes

Intervention

Device:
• No treatment

Locations

Country	Name	City	State
United States	Rainier Clinical Research Center	Rainier	Washington
United States	Diablo Clinical Research	Walnut Creek	California

Sponsors (1)

Lead Sponsor	Collaborator
Abbott Diabetes Care

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System compared to venous and capillary glucose	To demonstrate point accuracy of the Abbott Sensor Based Glucose Monitoring (GM) System interstitial glucose results against venous glucose reference (YSI) using the Consensus Error Grid.	14 days